The FDA’s War on Peptides: Why Banning BPC-157 and Other Compounds Hurts Everyone

They Don’t Want You Healing Yourself

In the last two years, the FDA has systematically moved to restrict access to some of the most promising healing compounds available. BPC-157. Thymosin Alpha-1. Thymosin Beta-4. Selank. Semax. Compounds that thousands of people have used safely, with extensive research backing, are being pulled from compounding pharmacies and pushed into regulatory gray zones.

This isn’t about safety. If it were about safety, they’d ban alcohol and cigarettes first. This is about control — and specifically about protecting pharmaceutical revenue streams from compounds that work too well and cost too little.

I’ve been in this fight for years. Enhanced Athlete got raided by the FDA. I’ve seen the inside of this machine. And I’m going to tell you exactly what’s happening and why you should care.

The Category 2 Designation — What It Actually Means

The FDA uses a system to categorize bulk drug substances for compounding pharmacies. Category 1 means a compound can be compounded. Category 2 means it’s under review or restricted. Category 3 means it’s banned from compounding.

In 2023-2024, the FDA moved several peptides to Category 2, including BPC-157 and various thymosin peptides. The practical effect is that compounding pharmacies — the primary legal source of pharmaceutical-grade peptides in the US — can no longer prepare these compounds for patients, even with a doctor’s prescription.

Think about that. A doctor evaluates a patient, determines that a well-researched peptide would benefit them, writes a prescription — and the FDA says no. Not because the compound is dangerous. Not because there were adverse events. Because it hasn’t gone through the multi-billion dollar FDA approval process that only pharmaceutical giants can afford.

Follow the Money

Why would the FDA crack down on peptides now? After decades of researchers and doctors using them safely?

Because peptides are becoming mainstream. When something that costs $30-50 per vial can replace treatments costing thousands per month, the pharmaceutical industry notices. And the FDA, for all its talk about public safety, has deep financial entanglements with the industry it’s supposed to regulate.

The FDA approval process for a new drug costs approximately $2-3 billion. That’s not a path designed for naturally occurring peptides that can’t be patented. No pharmaceutical company will invest billions to approve a compound they can’t monopolize. So the compound remains “unapproved” — and the FDA uses that “unapproved” status to restrict access.

It’s a circular trap. The compound can’t get approved because no one will fund the process. It can’t be legally accessed because it’s not approved. Meanwhile, patented pharmaceutical alternatives with worse side effect profiles sail through because they have billion-dollar companies lobbying for them.

The Safety Argument Doesn’t Hold Up

The FDA’s stated reason for restricting peptides is always safety. Let’s examine that claim.

BPC-157 has been studied since the early 1990s. Hundreds of peer-reviewed studies. Animal research showing tissue healing, neuroprotection, cardioprotection, and GI healing with no significant toxicity at therapeutic doses. Human case reports and clinical observations spanning decades with an excellent safety profile.

Compare that to FDA-approved drugs that get recalled every year after killing or injuring patients. The FDA approved opioids that created an addiction crisis killing tens of thousands of Americans annually. But a gastric peptide that heals tendons? That’s the danger they need to protect you from.

The argument is transparently dishonest. And anyone paying attention can see through it.

What This Means for You Right Now

If you’re in the US, the practical impact is significant. Compounding pharmacies that previously made pharmaceutical-grade BPC-157 and other peptides can no longer do so. Your options narrow to:

Research chemical suppliers. These operate in a legal gray zone, selling peptides “for research purposes only.” Quality varies enormously. Some are pharmaceutical-grade. Some are underdosed garbage. Without compounding pharmacy oversight, the burden of sourcing falls entirely on the consumer.

International sources. Peptides remain widely available in many countries. Here in Thailand, I have access to quality peptides through legitimate channels. Many people travel or order internationally. The Thailand supplement market is a world apart from the restricted US landscape.

Underground compounding. This is what prohibition always creates — an unregulated black market. When legitimate pharmacies can’t make a product, demand doesn’t disappear. It moves underground where there’s zero quality control. The FDA is literally making peptide use MORE dangerous by restricting regulated access.

The Body Autonomy Question

At its core, this is about whether adults have the right to make informed decisions about their own bodies.

I believe they do. I’ve always believed that. It’s why I built Enhanced Athlete. It’s why I moved my life to Thailand where personal freedom in this domain is respected. It’s why I continue to speak openly about the compounds I use and the results I see.

The paternalistic argument — that the government needs to protect people from themselves — falls apart when you look at what the government actually allows. Alcohol, tobacco, processed food engineered to be addictive, prescription drugs with lethal side effects. All legal. All heavily promoted. But a healing peptide? Too dangerous for adults to access.

I’m not anti-regulation. I’m anti-selective regulation that serves corporate interests while pretending to serve public health. There’s a massive difference.

Interesting Perspectives

The FDA’s war on peptides isn’t happening in a vacuum. It’s part of a broader pattern of regulatory capture that stifles innovation and protects legacy industries. Here are some unconventional angles on this fight:

The “Right to Try” Parallel: The 2018 federal Right to Try Act allows terminally ill patients to access investigational drugs. This legal framework, built on bodily autonomy, creates a fascinating philosophical contradiction. Why can a dying patient try an unapproved chemotherapy but a patient with a chronic, debilitating tendon injury can’t access a well-researched healing peptide like BPC-157? The inconsistency reveals that the gatekeeping isn’t about safety—it’s about what conditions and treatments the medical establishment deems legitimate.

Peptides as “Information Medicine”: Some biohackers and forward-thinking clinicians view peptides not as traditional drugs, but as signaling molecules that restore the body’s inherent communication networks. From this perspective, banning them is akin to censoring biological information. It’s a move against a paradigm of medicine that seeks to correct root-cause signaling errors rather than mask symptoms with patented synthetic molecules that often create new problems.

The Veterinary Loophole & The “Canary in the Coal Mine”: Many peptides restricted for human use remain readily available in veterinary medicine for racehorses, dogs, and livestock. This creates a two-tiered system where animal athletes receive cutting-edge regenerative therapies that human athletes are denied. Observant biohackers often look to the veterinary world as a leading indicator of efficacy and practical safety protocols, viewing it as a real-world testing ground that regulatory bodies for humans ignore.

The DIY Lab Movement: Increased restriction is fueling a decentralized “biohacker lab” movement. Individuals with scientific backgrounds are exploring open-source protocols for peptide synthesis and purity testing. While not without risk, this represents a radical shift towards personal sovereignty over biochemistry, directly challenging the FDA’s monopoly on defining what constitutes medicine. It’s the ultimate expression of the Tony Huge Laws of Biochemistry Physics—people will seek the biochemical tools that produce the physical results they desire, regardless of regulatory barriers.

What We Can Do

Stay informed. The regulatory landscape is shifting constantly. Organizations like the Alliance for Natural Health and various peptide advocacy groups track these changes and provide action items.

Support compounding pharmacy rights. Compounding pharmacies are the front line in this fight. They provide personalized, physician-supervised access to compounds that big pharma can’t or won’t make. When the FDA restricts compounding, patients lose.

Talk to your representatives. This sounds naive, but legislative pressure is the only counterweight to regulatory overreach. The younger generation is more open to performance enhancement and body autonomy than any before them. That political force can be mobilized.

Be transparent about your use. Stigma thrives in silence. The more people openly discuss responsible peptide use with their doctors, their peers, and online communities, the harder it becomes to paint these compounds as dangerous fringe substances. That’s why I’ve always been public about what I use. That’s why my Natty Plus philosophy exists — to normalize intelligent supplementation and enhancement.

Educate yourself on harm reduction. Whether you agree with the regulations or not, the reality is that many people will continue using peptides regardless. The responsible thing is to ensure they have accurate information about dosing, sourcing, side effects, and monitoring. Prohibition doesn’t work. Education does. I’ve been saying this since the supplement safety debate started years ago.

Where This Is Heading

I’d love to be optimistic, but the trend line isn’t great. The FDA has shown a pattern of escalating restrictions on research compounds. SARM legislation has been proposed multiple times. Peptide restrictions are expanding. The window for legal access is narrowing.

But here’s what I know from experience: prohibition creates resistance. The supplement freedom movement is growing. Medical professionals who’ve seen peptides work are speaking up. Patients who’ve healed injuries and resolved chronic conditions with these compounds aren’t going quietly.

The FDA can restrict compounding pharmacies, but they can’t restrict knowledge. They can’t restrict the research literature. And they can’t restrict the growing global community of people who’ve experienced the benefits firsthand.

This fight matters. Your body, your choice. That’s not just a slogan — it’s a principle worth defending.

Citations & References

U.S. Food and Drug Administration. (2023). Compounding: Bulk Drug Substances Under Section 503B of the FD&C Act. [Website]. Retrieved from FDA.gov. [Note: This is the primary source documenting the Category 2 designations for peptides discussed in the article].
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33. [Cited for the $2-3 billion drug development cost figure].
Sikiric, P., et al. (2014). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva). Current Pharmaceutical Design, 20(7), 1126-1135. [Review highlighting the extensive research history and safety profile of BPC-157].
Knezevic, M., et al. (2023. The controversial therapeutic journey of pentadecapeptide BPC 157. Pharmaceuticals, 16(1), 101. [Review discussing the clinical potential and regulatory challenges for BPC-157].
U.S. Congress. (2018). Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017. Public Law No: 115-176. [Legislative example of expanded access to unapproved therapies, creating a contrast with peptide restrictions].

Frequently Asked Questions

Is BPC-157 banned by the FDA?

BPC-157 hasn't received formal FDA approval as a pharmaceutical drug. However, it remains available through compounding pharmacies in a regulatory gray zone. The FDA has increased scrutiny of peptide compounds, making access increasingly restricted. It's legal to possess for research purposes, but therapeutic claims are prohibited without clinical approval.

What peptides has the FDA restricted or banned?

The FDA has targeted several peptides including BPC-157, Thymosin Alpha-1, Thymosin Beta-4, Selank, and Semax. These compounds were previously accessible through compounding pharmacies but face growing regulatory pressure. Most lack FDA-approved pharmaceutical status, placing them in unclear legal territory despite existing research demonstrating safety profiles.

Why is the FDA restricting peptide access?

The FDA prioritizes formal clinical trials and pharmaceutical approval pathways over compounded medications. Peptides exist in regulatory limbo without patent incentives for expensive drug trials. The agency argues this protects consumers from unproven treatments, but critics contend it restricts access to compounds with emerging research support and documented safety histories in other countries.

About Tony Huge

Tony Huge is a self-experimenter, biohacker, and founder of Enhanced Labs. He has spent over a decade researching and personally testing peptides, SARMs, anabolic compounds, nootropics, and longevity protocols. Tony’s mission is to push the boundaries of human potential through science, transparency, and direct experience. Follow his research at tonyhuge.is.